Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Andreessen Horowitz embraces ‘weak AI,’ diagnostics and cell circuits at launch of $750M fund

What AI, diagnostic and cell therapy opportunities could drive Andreessen Horowitz’s $750M Bio Fund III

February 5, 2020 2:09 AM UTC
Updated on Feb 5, 2020 at 7:08 PM UTC

With its third life sciences fund in four years, hybrid investment firm Andreessen Horowitz is looking to invest its $750 million Bio Fund III in multidisciplinary therapeutic, diagnostic and healthcare delivery companies whose approach to product development is more rooted in engineering than discovery.

Vijay Pande told BioCentury that designing technologies, instead of uncovering new biology or compounds, allows companies to take a longer view. “That approach allows you to be thinking down the line, all the way through payers.”...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article